Sandoz has now taken the final step in its long journey of separation from Novartis, becoming a standalone firm as it completed its spinoff from the former parent company. But as that process comes to an end, another journey is just beginning for Sandoz, as it sets out on its own as an independent global generics and biosimilars industry leader.
Key Takeaways:
-
Sandoz is now a standalone company, having formally been spun off from Novartis
The firm heralded a “new era as a standalone global leader and European champion in generic and biosimilar medicines” as...
